Bone News and Research

RSS

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Genzyme Corp.today said it welcomed the Centers for Medicare and Medicaid Services' decision not to include oral medications without IV equivalents in Medicare's End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme's Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014.

28 Jul 2010

New study reveals potential role of TGF-β1 in kidney disease

Fibrosis in the kidney is one of the key causes of progressive renal failure. High levels of the inflammatory molecule TGF-β1 in the kidney tubules due to tissue damage can cause fibrosis as well as nephron degeneration, resulting in loss of kidney function. To clarify the mechanisms regulating TGF-β1-mediated renal fibrosis, Koesters et al expressed high levels of TGF-β1 in renal tubules of mice. Nephron degeneration in this system was mediated by decomposition of the tubular cells. These data suggest that TGF-β1 may play a novel role in cell death of renal cells, thus contributing to renal fibrosis.

28 Jul 2010

CIHR grants $2.5 million to probe impact of physical activity on breast cancer

Over the next five years, a diverse, multi-disciplinary team of researchers led by Dr. Kerry Courneya of the University of Alberta and Dr. Christine Friedenreich of Alberta Health Services will conduct a series of five large research projects to probe the impacts of physical activity on breast cancer thanks to a $2.5 million team grant over five years from the Canadian Institutes of Health Research (CIHR).

28 Jul 2010

Growth in dental implant sales to propel bone-graft-substitute market

According to new dental reports by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for dental implants is expected to regain double-digit growth by 2013, and will help drive the dental prosthetic market to reach over 82 million prosthetic placements by 2016.

27 Jul 2010

Four research teams to study role of exercise in preventing, treating chronic diseases

Canadians will benefit from new insights into the link between physical activity and health as the Honourable Leona Aglukkaq, Minister of Health, today announced funding for four research teams through the Canadian Institutes of Health Research. These teams will study the effects of exercise on the body and its role in the prevention and treatment of chronic diseases including arthritis, breast cancer and heart disease.

27 Jul 2010

New drug for type 2 diabetes, Effect of insulin on bones

In a groundbreaking finding, a new medicine Galvus (vildagliptin) has been created for people with type 2 diabetes that would lower blood glucose levels without the side effects of other medications.

26 Jul 2010

Orthovita's PMA supplement for new collagen processing facility receives FDA approval

Orthovita, Inc., an orthobiologics and biosurgery company, reported today that the U.S. Food and Drug Administration (FDA) approved Orthovita's PMA supplement for a new collagen processing facility in Malvern, Pennsylvania. Orthovita will use the new facility to process the highly purified form of collagen used in its VITAGEL™ Surgical Hemostat product. VITAGEL is a composite liquid hemostat used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

26 Jul 2010

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

26 Jul 2010

New guidelines for care of heart transplant recipients from ISHLT

Since the dawn of heart transplantation in the 1960s, medical care of heart transplant recipients has varied from center to center and been guided by the experience of individual clinicians. The International Society for Heart and Lung Transplantation (ISHLT) has made an unprecedented commitment by convening experts in all areas of heart transplantation to develop practice guidelines for the care of heart transplant recipients.

26 Jul 2010

Study focuses on health issues of PGDP workers

A five-year study into the causes of deaths of workers at Paducah Gaseous Diffusion Plant shows significantly lower death rates from all causes and cancer in general when compared to the overall United States population. This is known by occupational health researchers as the "healthy worker effect". However, death from lymphatic and bone marrow cancers such as leukemia or multiple myeloma were slightly above national rates.

23 Jul 2010

Insulin action may provide link between bone health, metabolic disease: Study

A new study by Johns Hopkins researchers has found that insulin, the sugar-regulating hormone, is required for normal bone development and that it may provide a link between bone health and metabolic disease, such as diabetes.

23 Jul 2010

NVCI, CSN and Workforce CONNECTIONS partner to launch ARRA funded nursing internship program

Nevada Cancer Institute (NVCI) is launching its Plus One Program, a paid nursing internship initiative to equip nursing graduates with advanced training to give them an edge in today's competitive nursing job market. After completing a paid one-year internship at NVCI, participants will become oncology nurses, a highly sought-after specialty. These specialized jobs have the potential to pay increased wages, provide excellent benefits and support articulated career ladders within the field of oncology.

23 Jul 2010

Kaiser Permanente's Total Joint Replacement Registry enhances patient safety, quality of care

A total joint replacement registry based on carefully designed and integrated technology can enhance patient safety, quality of care, cost-effectiveness and research, according to a paper published in the online and print editions of Clinical Orthopedics and Related Research, a journal of the Association of Bone and Joint Surgeons.

23 Jul 2010

ASH to honor six scientists for treatment of hematologic diseases

The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding and treatment of hematologic diseases. These awards will be presented at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando.

23 Jul 2010

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx's oncology drug candidate tamibarotene.

23 Jul 2010

Poor intake of vitamins tends to have low bone density in children with celiac disease

Children with celiac disease need to include certain must-have vitamins in their diets to stave off weak bones and osteoporosis, say researchers at the University of Alberta. A study of 43 children and teens from three to 18 years of age diagnosed with celiac disease showed that they also tended to have low bone density, likely due to poor intake and absorption of vitamins and minerals. That means they should be getting more of bone-boosting vitamins such as K and D in their diets, says Diana Mager, a professor of agricultural, food and nutritional science at the U of A, and one of the researchers on the project.

23 Jul 2010

Osteocalcin hormone can regulate glucose levels: Research

Researchers led by Columbia University Medical Center have discovered that the skeleton plays an important role in regulating blood sugar and have further illuminated how bone controls this process. The finding, published in Cell, is important because it may lead to more targeted drugs for type 2 diabetes.

23 Jul 2010

Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.

22 Jul 2010

Repros granted IRB approval to commence low dose Proellex study

Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.

22 Jul 2010

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.

22 Jul 2010

Bone News and Research

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

New study reveals potential role of TGF-β1 in kidney disease

CIHR grants $2.5 million to probe impact of physical activity on breast cancer

Growth in dental implant sales to propel bone-graft-substitute market

Four research teams to study role of exercise in preventing, treating chronic diseases

New drug for type 2 diabetes, Effect of insulin on bones

Orthovita's PMA supplement for new collagen processing facility receives FDA approval

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

New guidelines for care of heart transplant recipients from ISHLT

Study focuses on health issues of PGDP workers

Insulin action may provide link between bone health, metabolic disease: Study

NVCI, CSN and Workforce CONNECTIONS partner to launch ARRA funded nursing internship program

Kaiser Permanente's Total Joint Replacement Registry enhances patient safety, quality of care

ASH to honor six scientists for treatment of hematologic diseases

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Poor intake of vitamins tends to have low bone density in children with celiac disease

Osteocalcin hormone can regulate glucose levels: Research

Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

Repros granted IRB approval to commence low dose Proellex study

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News